Abstract:Background: The study of high-throughput genomic profiles from a pharmacogenomics viewpoint has provided unprecedented insights into the oncogenic features modulating drug response. A recent study screened for the response of a thousand human cancer cell lines to a wide collection of anti-cancer drugs and illuminated the link between cellular genotypes and vulnerability. However, due to essential differences between cell lines and tumors, to date the translation into predicting drug response in tumors remains challenging. Recently, advances in deep learning have revolutionized bioinformatics and introduced new techniques to the integration of genomic data. Its application on pharmacogenomics may fill the gap between genomics and drug response and improve the prediction of drug response in tumors. Results: We proposed a deep learning model to predict drug response (DeepDR) based on mutation and expression profiles of a cancer cell or a tumor. The model contains three deep neural networks (DNNs), i) a mutation encoder pre-trained using a large pan-cancer dataset (The Cancer Genome Atlas; TCGA) to abstract core representations of high-dimension mutation data, ii) a pre-trained expression encoder, and iii) a drug response predictor network integrating the first two subnetworks. Given a pair of mutation and expression profiles, the model predicts IC50 values of 265 drugs. We trained and tested the model on a dataset of 622 cancer cell lines and achieved an overall prediction performance of mean squared error at 1.96 (log-scale IC50 values). The performance was superior in prediction error or stability than two classical methods (linear regression and support vector machine) and four analog DNN models of DeepDR, including DNNs built without TCGA pre-training, partly replaced by principal components, and built on individual types of input data. We then applied the model to predict drug response of 9059 tumors of 33 cancer types. Using per-cancer and pan-cancer settings, the model predicted both known, including EGFR inhibitors in non-small cell lung cancer and tamoxifen in ER+ breast cancer, and novel drug targets, such as vinorelbine for TTN-mutated tumors. The comprehensive analysis further revealed the molecular mechanisms underlying the resistance to a chemotherapeutic drug docetaxel in a pan-cancer setting and the anti-cancer potential of a novel agent, CX-5461, in treating gliomas and hematopoietic malignancies. Conclusions: Here we present, as far as we know, the first DNN model to translate pharmacogenomics features identified from in vitro drug screening to predict the response of tumors. The results covered both well-studied and novel mechanisms of drug resistance and drug targets. Our model and findings improve the prediction of drug response and the identification of novel therapeutic options.

Prediction of Drug Response with a Topology Based Dual-Layer Network Model.

DualGCN: a dual graph convolutional network model to predict cancer drug response

Predicting breast cancer drug response using a multiple-layer cell line drug response network model

Dual-Layer Strengthened Collaborative Topic Regression Modeling for Predicting Drug Sensitivity

A Novel Approach For Drug Response Prediction In Cancer Cell Lines Via Network Representation Learning

A novel heterogeneous network-based method for drug response prediction in cancer cell lines

An Improved Anticancer Drug-Response Prediction Based on an Ensemble Method Integrating Matrix Completion and Ridge Regression

DBDNMF: A Dual Branch Deep Neural Matrix Factorization method for drug response prediction

Predicting drug response of tumors from integrated genomic profiles by deep neural networks

Towards a Better Model with Dual Transformer for Drug Response Prediction

Decoding Drug Response with Structurized Gridding Map-based Cell Representation.

Drug cell line interaction prediction

TCR: A Transformer Based Deep Network for Predicting Cancer Drugs Response

Improving drug response prediction based on two-space graph convolution

DRN-CDR: A cancer drug response prediction model using multi-omics and drug features

DeepCDR: a Hybrid Graph Convolutional Network for Predicting Cancer Drug Response

DeepTTA: a transformer-based model for predicting cancer drug response

Predicting drug synergy using a network propagation inspired machine learning framework

Hi-GeoMVP: a hierarchical geometry-enhanced deep learning model for drug response prediction

Predicting cancer drug response using parallel heterogeneous graph convolutional networks with neighborhood interactions

Learning the Cellular Activity Representation Based on Gene Regulatory Networks for Prediction of Tumor Response to Drugs